I'm pretty sure if they add efficacy endpoints to Phase I, it becomes a Phase I/Phase II and the efficacy is for Phase II. The other problem with efficacy in Ph

I'm pretty sure if they add efficacy endpoints to Phase I, it becomes a Phase I/Phase II and the efficacy is for Phase II. The other problem with efficacy in Phase I is that alzheimer's efficacy is not measured over such short time frames.